Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 490 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: promethazine Clear all

Conditions: Fibrosis
Interventions: BMS-986263, Placebo, Diphenhydramine, Famotidine; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cypress, California

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT; Drug · Other
Lead sponsor: Hearn Jay Cho; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia
Interventions: Isatuximab SAR650984, dexamethasone, acetaminophen, ranitidine, diphenhydramine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 3
States / cities: Atlanta, Georgia • Hackensack, New Jersey • Houston, Texas

Conditions: Posttraumatic Stress Disorder, Depression, Alcohol-Related Disorders, Suicidal Ideation, Substance-Related Disorders, Mild Cognitive Impairment, Quality of Life, Pain, Wounds and Injury, Brain Injuries, Chronic Disease
Interventions: Motivational Interviewing, Cognitive Behavioral Therapy Elements, Care Management, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Citalopram, Venlafaxine, Duloxetine, Mirtazapine, Diphenhydramine, Trazodone, Prazosin; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 24
States / cities: Scottsdale, Arizona • Beverly Hills, California • Sacramento, California + 20 more

Conditions: Hypertension
Interventions: Irbesartan/HCTZ, Irbesartan monotherapy; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 156
States / cities: Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 153 more

Conditions: Pompe Disease
Interventions: Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, Rapamycin, saline, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream; Genetic · Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Renal Transplant
Interventions: Belatacept, Sirolimus, Anti-thymocyte globulin, methylprednisolone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: San Francisco, California • Atlanta, Georgia

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Sacituzumab tirumotecan, Docetaxel, Pemetrexed; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 16
States / cities: Los Angeles, California • Jacksonville, Florida • Orange City, Florida + 13 more

Conditions: Headache
Interventions: Metoclopramide, Diphenhydramine, Codeine; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 16 Years to 50 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lupus Erythematosus, Systemic
Interventions: Rituximab, Placebo, Prednisone, Acetaminophen, Diphenhydramine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 63
States / cities: Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 51 more

Conditions: Pharyngitis
Interventions: placebo, flurbiprofen, acetaminophen 650mg; Drug
Lead sponsor: Reckitt Benckiser LLC; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Tazemetostat, Liposome-encapsulated Daunorubicin-Cytarabine, Bone Marrow Aspiration and Biopsy, Biospecimen Collection, Palbociclib; Drug · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sex Differences
Interventions: Compound 21, Compound 21 + losartan; Drug
Lead sponsor: Anna Stanhewicz, PhD; Other
Eligibility: 18 Years to 35 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Hypertension
Interventions: Ramipril, Telmisartan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 55 Years and older
Enrollment: 63,744 participants
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions: Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more

Conditions: Transient Insomnia
Interventions: SM-1, D+Z, D+L, Placebo; Drug
Lead sponsor: Sequential Medicine Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Osteoarthritis, Knee
Interventions: Fisetin, Losartan, Placebo - Losartan, Placebo Fisetin; Drug
Lead sponsor: Steadman Philippon Research Institute; Other
Eligibility: 40 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Vail, Colorado

Conditions: Liver Transplant Recipients
Interventions: Cozaar; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Headache
Interventions: Metoclopramide, Ketorolac; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 21 Years to 64 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Distal Radius Fracture
Interventions: Opiate Sparing, Opiate Based; Other
Lead sponsor: Campbell Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Germantown, Tennessee

Conditions: Sarcopenia
Interventions: Losartan, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 70 Years to 100 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: Aliskiren, Irbesartan, Captopril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hairy Cell Leukemia
Interventions: Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience, Dexamethasone, Acetaminophen, Diphenhydramine, Famotidine, Aspirin; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Burn Scar, Itch Scarring, Wound
Interventions: Famotidine and 4% topical cromolyn sodium, Placebo; Combination Product · Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Galveston, Texas

Search by objective public record fields.

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

Belatacept to Prevent Organ Rejection in Kidney Transplant Patients

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis

Tazemetostat and Palbociclib With CPX-351for R/R AML

Sex Differences in the Dilatory Response of Compound 21

Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.

Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis

The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant

Metoclopramide Versus Ketorolac for Tension-type Headache

Opiate Sparing Protocol Randomized Controlled Trial in Open Distal Radius Fracture Repair

A Study of Muscle Strength Maintenance in Older Adults

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Novel Strategies for Reducing Burn Scar Itch